

**August 07, 2024**

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
*Scrip Code: 524742*

**National Stock Exchange of India Ltd.,**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
*Scrip Code: CAPLIPOINT.*

Dear Sir/Madam,

**Sub: Re-appointment of Managing Director of the Company – Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the SEBI Listing Regulations”)**

Pursuant to Regulation 30(6) read with Schedule III of the SEBI Listing Regulations, we hereby inform you that basis the recommendations of the Nomination and Remuneration Committee, the Board, at their meeting held today, i.e. August 07, 2024, approved the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company, liable to retire by rotation, for a period of 2 (two) years with effect from August 25, 2024 to August 24, 2026 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing 33<sup>rd</sup> Annual General Meeting of the Company.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as “Annexure- A”.

This is for your kind information and records.

Thanking You,

Sincerely yours,

**For Caplin Point Laboratories Limited**

**Venkatram G**  
**General Counsel & Company Secretary**  
**Membership No. A23989**

**Annexure – A**

Sr. No.	Particulars	Details
1.	Reason for change <del>viz. appointment, re-appointment, resignation, removal, death or otherwise</del>	Re-appointment of Dr. Sridhar Ganesan as Managing Director
2.	Date of <del>appointment/re-appointment/cessation (as applicable) &amp; term of appointment/re-appointment;</del> appointment/re-appointment;	August 25, 2024  Term: 2 Years commencing from August 25, 2024 to August 24, 2026 (both days inclusive)
3.	Brief profile	Dr. Sridhar Ganesan has over 40 years of varied global leadership experience in the Pharmaceutical Industry, including but not limited to, Profit center Management, Global Marketing, Middle East and African engagement, international collaborative and cooperative relationship-building, new pharmaceutical project planning & implementation, production, new product development, Quality Assurance and Factory Management.  Being the Managing Director of the company he had spearheaded its rapid growth with a global footprint. Previously, he had held leadership positions in several international assignments and has expertise not only in the industry but also in unique needs of developing countries in South Asia, Middle East and Africa.
4.	Disclosure of relationships between directors (in case of appointment of a director).	Dr. Sridhar Ganesan is not related inter-se to any other Director of the Company.
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Dr. Sridhar Ganesan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.